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Long QT syndrome type 3 (LQT3) results from gain-of-
function mutations in the SCN5A gene, which encodes the
major cardiac sodium channel, voltage-gated type V alpha
subunit (NaV 1.5). Those mutations result in an increase in
late sodium channel current, which leads to delayed ven-
tricular repolarization, torsades de pointes (TdP), and
sudden death.
Traditionally, beta-blockers mexiletine and phenytoin
have been the agents of choice in the management of
LQT3. Ranolazine is a novel antianginal drug that has been
shown to have multichannel blocking effects, including the
late sodium channel current (INa,L) and the rapid delayed-
rectiﬁer potassium current (IKr). The extended-release for-
mulation of ranolazine has a half-life of 7 hours. It has been
used in adults with LQT3 1; however, there are currently no
published data on its use in the pediatric population. Data
have shown that ranolazine is more effective in inhibiting the
late vs the peak Naþ current in LQT3 caused by SCN5A
mutations. We theorize that use of ranolazine in an infant
with LQT3 and persistent TdP refractory to multiple
medications would be effective. We report that ranolazine
use in infants is very difﬁcult and found that phenytoin was
the most effective agent in our patient.
Case report
A full-term female infant was delivered by emergency
caesarean section owing to fetal bradycardia. Initial cardiac
assessment revealed 2:1 atrioventricular block (atrial rate
120 and ventricular rate 60) and corrected QT of 690
milliseconds (Figure 1) with short episodes of TdP. Echo-
cardiogram showed severely depressed left ventricular
function with otherwise normal intracardiac anatomy. There
was no family history of sudden death or long QT syndrome
and both parents had normal electrocardiograms.KEYWORDS Long QT; Ranolazine; Sodium channel; Pharmacology;
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).Genetic testing identiﬁed an SCN5A c.A4424C variant
resulting in p.Q1475P missense mutation in the NaV1.5
inactivation gate (DIII/DIV, interlinker domain). In addition,
a KCNH2, c.A2690C, p.K897T polymorphism was
detected, the gene coding for the hERG potassium channel
(IKr). No mutations were identiﬁed in KCNQ1, KCNE1,
and KCNE2.
The patient was initially treated with isoproterenol,
magnesium, and propranolol; however, episodes of TdP
persisted. The sodium channel blocker mexiletine was
added, followed by ﬂecainide. However, QTc remained
prolonged, with T-wave alternans and TdP. As the ﬂecainide
was increased there was widening of the QRS duration, so it
was discontinued. She then underwent epicardial dual-
chamber implantable cardioverter-deﬁbrillator / pacemaker
implantation in combination with a left cardiac sympathetic
denervation. AAI pacing to augment heart rate led to 2:1
atrioventricular block and VVI pacing increased episodes of
TdP. Ultimately she was left on backup AAI pacing at 100
beats per minute. Episodes of TdP persisted, so ranolazine
was started. Initially a low dose (2–25 mg/kg/day, every 12
hours) was used, but the plasma trough level was low
(Table 1), with no clinical effect. The dose was increased
and the dosing interval decreased (50 mg/kg/day, every 6
hours), with a reduction in episodes of TdP, though the QTc
remained prolonged with frequent T-wave alternans. She
was discharged home at 2.5 months of age on propranolol 3
mg/kg/day every 6 hours, mexiletine 30 mg/kg/day every 8
hours, and ranolazine 50 mg/kg/day every 6 hours.
After discharge, she had multiple episodes of TdP,
2 of which required deﬁbrillation despite a maximal
ventricular ﬁbrillation detection interval of 30 seconds.
The ranolazine dose was increased to 60 mg/kg/day, with
levels showing appropriate peak levels but still with low
trough levels.
At 1 year of age, she was noted again to have frequent
episodes of TdP, 1 of which required deﬁbrillation. This
occurred just before a scheduled dose of ranolazine. In
addition, T-wave alternans was still present. After review of
prior ranolazine levels and knowing that the elimination half-
life was 1.4–1.9 hours, it became clear that in order topen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Ranolazine is a late sodium channel blocker that
has potential use in long QT syndrome type 3 with
mutation affecting the late sodium current.
 Ranolazine use in pediatrics is limited by short
half-life of the immediate-release form and may
require frequent dosing or the addition of a
cytochrome P450 3A inhibitor.
 Phenytoin can be used in refractory cases of
long QT.
Heart Rhythm Case Reports, Vol 0, No 0, Month 20162increase the trough level, dosing would have to be changed
to every 4 hours. This was not practical on a long-term basis,
so we chose to try and boost the trough level by adding a
cytochrome P450 (CYP) 3A inhibitor, as ranolazine is
metabolized by the CYP3A enzyme system. The CYP3A
inhibitor verapamil was chosen. Verapamil was started at 4
mg/kg/day divided over every 8 hours. The ranolazine level
obtained showed increased trough and peak levels, but the
patient developed increasing episodes of TdP, which we
attributed to high-afﬁnity block of hERG by verapamil
(Table 1). She subsequently had a prolonged admission
owing to frequent arrhythmia storms. She had multiple daily
episodes of TdP that were managed with cardiopulmonary
resuscitation to avoid frequent deﬁbrillation and weekly
storm events requiring deﬁbrillation. Verapamil was discon-
tinued and diltiazem, a CYP3A inhibitor that weakly blocks
hERG, was started. She continued to have arrhythmia stormsFigure 1 Initial electrocardiogram revealing bradycardia with 2:1 atrioventriculwith high levels of ranolazine, suggesting possible proar-
rhythmia at elevated levels, so the ranolazine dose was
decreased. Phenytoin, a third sodium channel blocker, was
initiated. At lower levels of ranolazine with therapeutic
mexiletine and phenytoin levels, arrhythmia control was
achieved. This admission was complicated by seizures,
likely owing to elevated mexiletine levels. Mexiletine
dose was decreased and she was later placed on anti-
seizure medications levetiracetam and topiramate. The
addition of phenytoin occurred after seizure control had
been achieved.
With a regimen of ranolazine, mexiletine, phenytoin,
diltiazem, and propranolol, we have reduced the patient’s
arrhythmia burden from 450 episodes per day to zero
(Figure 2). After 6 months of control, ranolazine and
diltiazem were discontinued, and there have been no TdP
episodes in the last 2 months. She is currently on a regimen
of mexiletine 10 mg/kg/dose every 8 hours, phenytoin 4 mg/
kg/dose every 8 hours, and propranolol 1 mg/kg/dose every 8
hours. She continues to have prolonged QT with a QTc of
595 msec (Figure 3).Discussion
To our knowledge, this is the ﬁrst reported use of ranolazine
in an infant with severe LQT3. We discovered the complex-
ities of using ranolazine in infants, related to its short half-life
as well as drug interactions. We also characterized the
pharmacokinetics of ranolazine in infants and describe the
use of a CYP3 inhibitor to extend the half-life. Finally, we
found that phenytoin was more efﬁcacious than ranolazine.ar block and prolonged QT with isolated premature ventricular contractions.
Table 1 Ranolazine levels
Drug Dose (mg/kg/day) / Time interval
Ranolazine 12/q12h 12/q6h 60/q6h 70/q6h 88/q6h 88/q6h 60/q6h 80/q6h
Verapamil 4/q8h 4/q8h
Diltiazem 3/q8h 3/q6h 3/q6h
Phenytoin 12/q8h 12/q8h
Time interval Level (ng/mL)
Trough BQL 146 312 862 2220 517 o50 76
1 h post 1180 1300 2160 2830 2260 2030
2 h post 573 2080 571 368
3 h post 269
4 h post 4140 o50
BQL = below quantiﬁcation limit (o50 mg/mL); q6h ¼ every 6 hours; q8h ¼ every 8 hours; q12h ¼ every 12 hours.
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diagnosis of LQT3 was made and treatment with Naþ
channel blockers and beta-blockers initiated. Genetic testing
later conﬁrmed the diagnosis with mutation in the inactiva-
tion gate of the sodium channel (p.Q1475P) as well as a
polymorphism in hERG. Bankston et al 2 reported a patient
with a similar clinical history that had a missense mutation 2
amino acid residues away from our patient’s mutation in the
inactivation gate of NaV1.5 (p.F1473C) and the same hERG
polymorphism. Patch clamp testing of NaV1.5 (p.F1473C)
function revealed marked increase in the late sodium channel
current as well as faster recovery for inactivation, both
contributing to delayed repolarization. Pharmacologic
response of the mutant channel to different Naþ channel
blockers was determined. Ranolazine, mexiletine, and ﬂe-
cainide all preferentially inhibited the late vs peak NaFigure 2 Timeline of signiﬁcant events in months vs arrhythmia burden. ICD
denervation; PM ¼ pacemaker; Tdp ¼ torsades de pointes.channel currents. However, ranolazine and mexiletine causes
hyperpolarizing shifts in the voltage-dependent steady-state
inactivation, which leads to restoration of closed-state
inactivation, whereas ﬂecainide displayed no such effect,
making it an ineffective drug for this mutation.2 Similar
clinical response was noted in our patient.
The polymorphism in KCNH2 (p.K897T) is common and
has been extensively studied; however, data have been
conﬂicting as to how it affects hERG channel function.
Some studies have shown that although the mutation does
not typically cause disease by itself, when combined with
QT-prolonging drugs or coinheritance of a long QT syn-
drome mutation it may accentuate the effects of reduced
repolarization reserve.3,4
Ranolazine is a new antianginal drug with novel electro-
physiologic properties and is known to inhibit a number of ion¼ implantable cardioverter-deﬁbrillator; LCSD ¼ left cardiac sympathetic
Figure 3 Electrocardiogram showing A-paced rhythm at a rate of 100 beats per minute with QTc of 595 msec.
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shorten the QTc interval in a concentration-dependent manner.
In a study by Moss et al,5 QTc shortened at peak plasma
concentrations between 908 and 2074 ng/mL; however, there
were no data with higher concentration levels beyond the
therapeutic concentration used for treatment of angina. Phar-
macokinetics have been studied extensively in adults, with peak
concentrations of immediate-release preparations noted 1 hour
after oral administration. Elimination half-life is 1.4–1.9 hours
for immediate-release preparations and 7 hours for extended-
release preparations. Its bioavailability is 35%–50% and it is
renally excreted and metabolized by CYP3A enzymes.6
Dosing for the extended-release formulation is twice a day.
For our patient, a suspension was made by crushing extended-
release tablets and adding sterile water and Ora-Plus (Perrigo
Australia; Perth, Australia). Dosing was initially extrapolated
from adult dosing and then tailored based on drug levels and
clinical response of the patient.
Because the metabolism of ranolazine was unknown in
infants, we started dosing every 12 hours and were able to
check plasma levels courtesy of Gilead Science. Initial levels
obtained showed peak levels occurring at 1 hour, with the
half-life (as estimated by earlier studies) at approximately 2
hours. Decreasing the dosing interval from every 12 hours to
every 6 hours mildly increased trough levels while signiﬁ-
cantly increasing the peak levels. Because steady-state levels
could not be obtained with the short-acting preparation, we
decided to add a CYP3A inhibitor to increase the half-life and
obtain higher trough levels. Our choice of CYP3A inhibitor
was based on pharmacokinetic studies by Jerling 6 and Gilead
Science. Verapamil and diltiazem are CYP3A inhibitors that
increase ranolazine exposure by 100% and 50%–130%,respectively. Both are also antagonists of the delayed-
rectiﬁer potassium current. In a study by Zhang et al,7 they
showed that verapamil is a potent antagonist of the hERG
channel, whereas diltiazem only weakly suppresses it. With
the addition of verapamil, the initial levels showed appropriate
trough and peak levels with clinically good control at that
time. However, prolonged exposure to verapamil led to
elevated steady-state levels that were beyond the peak plasma
concentrations studied in adults. This is presumably a result of
use-dependent drug binding leading to the frequency-
dependent effects of verapamil on hERG current.7 We
hypothesize that the elevated ranolazine levels may have
had proarrhythmic effects coupled with proarrhythmia from
verapamil. On switching to diltiazem, peak concentrations are
noted at 4 hours. However, episodes of torsades persisted even
with adequate trough and very high peak ranolazine levels.
As a ﬁnal desperate measure we added phenytoin, and
there was complete cessation of torsades. Phenytoin has a
half-life of 12–36 hours and is a commonly used anticon-
vulsant with class IB antiarrhythmic properties that has been
used in patients with refractory ventricular arrhythmias. It
has effects on Naþ, Ca2þ, and Kþ channels in cardiac
myocytes and Purkinje ﬁber cell membranes. Inhibition of
rapid inward Naþ current shortens the action potential and
reduction of voltage-dependent calcium current reduces the
rate of depolarization in the plateau phase of the cardiac
action potential and increases the refractory period, thus
preventing EADs.8 The phenytoin trough level was main-
tained at the high therapeutic range (15–20 mcg/mL). The
addition of phenytoin resulted in a marked decline in
ranolazine levels, as phenytoin is a potent inducer of
CYP3A. There were no further episodes of TdP on
5Tan et al Ranolazine and Phenytoin Use in an Infant With Long QT Syndrome Type 3phenytoin and mexiletine with a low dose of ranolazine, so
after 5 months the ranolazine and diltiazem were discon-
tinued, with no recurrence of torasdes after 2 months of
follow-up. In our patient the addition of phenytoin was the
ﬁnal drug needed to achieve rhythm control.
Conclusion
The use of ranolazine in infants proves difﬁcult owing to its short
half-life and drug interactions leading to signiﬁcant proarrhythmic
side effects. In our patient we were unable to show a sustained
positive therapeutic effect with ranolazine. Its efﬁcacy may be
greatest in thosewith isolated SCN5Amutations affecting the late
sodium current. Caution must be used in patients with multiple
mutations or additional polymorphisms owing to its multichannel
effect. However, the pharmacokinetics would require every-4-
hour dosing. The addition of a CYP3A inhibitor, such as
verapamil or diltiazem, can extend the half-life to allow for
every-6-hour dosing. Alternative CYP3A inhibitors can be
considered as well, such as omeprazole. Finally, phenytoin
should be considered in cases of malignant infant LQT3.
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